Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
Daix (France), Long Island City (New York, United States), June 9, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that three abstracts have been selected for poster presentation at the upcoming International Liver CongressTM 2022 hosted by the European Association for the Study of the Liver (EASL) on June 22-26, 2022 in London, UK.
The first abstract focuses on the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with NASH showing that they are independent of weight change. Based on the results of Inventiva’s NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH, the authors of the abstract analysed markers of cardiometabolic health in relation with the weight variation observed in patients treated with lanifibranor or on placebo. The treatment with lanifibranor showed beneficial effects on biomarkers of cardiometabolic health, including markers of lipid and glucose metabolism, insulin resistance and inflammation independent of weight change. These beneficial effects occurred in parallel with an increase of adiponectin levels demonstrating an improvement in adipose tissue health. These results provide further evidence that PPARγ-induced weight gain is associated with improved insulin sensitivity, i.e. is metabolically healthy and thus distinct from lifestyle-related weight gain.
Download PDF